Abstract:Abstract Introduction and objectives: There is increasing evidence that chronic activation of sympathetic neurons can lead to increased noradrenaline levels in the tumor microenvironment (TME) in PDAC. However, the mechanisms by which adrenergic neurotransmitters are delivered to the TME are not well understood. In this study we aimed to investigate the effect of locally and systemically delivered catecholamines into the TME in two well established genetically engineered mouse models of PDAC (Pdx1-Cre/KRasG12D (KC) and Pdx1-Cre/KRasG12D/Trp53R172H (KPC)). Methods: Adrenergic signaling was induced or inhibited in KC or KPC mice and in pancreatic organoids using various pharmacological compounds. Adrenergic receptor expression was assessed by RT-PCR, WB and IHC. Downstream pathways were identified by phosphorylation assays and WB. Adrenergic signaling was modeled in vivo applying restraint stress. To elucidate the crosstalk between nerves and cancer cells, pancreatic spheres and PDAC cells were co-cultured with DRGs and neuronal plasticity was quantified. NGF secretion was measured by RT-PCR and ELISA. Sympathetic denervation of the pancreas and blockage of the 2-receptor was employed as a treatment strategy in KPC mice. Overexpression of NGF was targeted to the mouse pancreas using a novel NGF knockin mouse, which was crossed to KC and KPC mice. Results: ADRB2 was upregulated during pancreatic cancer development. Furthermore, in vitro stimulation of cells harboring an oncogenic KRas mutation with catecholamines resulted in significantly increased sphere forming efficiency. The non-specific -blocker propranolol and the selective 2-blocker ICI 118,551 inhibited this effect. Selective blockade of 2-adrenergic signaling suppressed pancreatic sphere formation caused by co-cultures with DRGs. NGF secretion was stimulated through beta2-adrenergic signaling. Furthermore, restraint stress accelerated PDAC development in KC mice. The effects of stress were prevented by treatment with the selective ADRB2 antagonist ICI 118,551. Specific β2-blocker treatment as well as sympathetic denervation in addition to GEM significantly increased the survival of mice with 3-5 mm tumors in comparison to controls treated by GEM alone. Targeted overexpression of NGF in the mouse pancreas using a novel NGF knockin mouse resulted in marked acceleration of PanIN lesions in the KC mouse and shortened overall survival in KPC mice significantly. Finally, retrospective analysis of a PDAC patient cohort revealed a extension of overall survival in PDAC patients on non-selective -blockers. Conclusions: Taken together, these studies suggest that increased catecholamines can engender a feed forward loop, whereby upregulation of NGF can lead to increased innervation and local NE accumulation, thereby enhancing tumor growth. Therapies targeting these adrenergic and NGF pathways may prove useful in the treatment and prevention of pancreatic cancer. Citation Format: Bernhard W. Renz, Marina Macchini, Yoku Hayakawa, Xiaowei Chen, Zhengyu Jiang, Takayuki Tanaka, C. Benedikt Westphalen, Yagnesh Tailor, Jens Werner, Axel Kleespies, Alina C. Iuga, Daniel L. Worthley, Kenneth P. Olive, Timothy C. Wang. A novel β 2 adrenergic-nerve growth factor feed forward loop promotes pancreatic cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 5111.

Targeting Arachidonic Acid Pathway-Associated NF-κB in Pancreatic Cancer

Advancement of NF-κB Signaling Pathway: A Novel Target in Pancreatic Cancer

NF-κB Mediated Disruption of Pancreatic Signaling Pathways and its Implications for the Risk of Pancreatic Adenocarcinoma: a systematic review

Targeting arachidonic acid pathway by natural products for cancer prevention and therapy

p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation

NF-κB Relative Signal Pathway and Pancreatic Cancer

PP2A Inhibitors Induce Apoptosis in Pancreatic Cancer Cell Line PANC-1 Through Persistent Phosphorylation of IKKα and Sustained Activation of the NF-κB Pathway.

Targeting The Key Factors Of Inflammation In Cancer: Plant Intervention

Dual Roles and Therapeutic Potential of Keap1-Nrf2 Pathway in Pancreatic Cancer: a Systematic Review

AHNAK2 Regulates NF-κB/MMP-9 Signaling to Promote Pancreatic Cancer Progression

Recent advances in drug delivery and targeting for the treatment of pancreatic cancer

Arachidonic acid metabolism as a novel pathogenic factor in gastrointestinal cancers

Integrated proteomic profiling identifies amino acids selectively cytotoxic to pancreatic cancer cells

Targeted Therapeutic Approaches for the Deadliest Cancer

Inflammation-Related Pancreatic Carcinogenesis

Targeting sphingosine 1-phosphate and sphingosine kinases in pancreatic cancer: mechanisms and therapeutic potential

Abstract 5111: A Novel Β 2 Adrenergic-Nerve Growth Factor Feed Forward Loop Promotes Pancreatic Cancer

Application of the Targeted Next Generation Sequencing to the Comprehensive Analysis of Pancreatitis Susceptibility Genes

Multifaceted Effects of Kinase Inhibitors on Pancreatic Cancer Cells Reveals Pivotal Entities with Therapeutic Implications

Inflammation-Related Pancreatic Carcinogenesis: Mechanisms and Clinical Potentials in Advances.

Targeting a transcription factor NF-κB by green tea catechins using in silico and in vitro studies in pancreatic cancer